IP Library › Granted Patent US 9,976,188
Granted Patent B2
US 9,976,188 · App. 15/588,458 · Granted May 22, 2018

Cancer biomarkers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,976,188
App. No.
15/588,458
Granted
May 22, 2018
Kind
B2
Abstract

Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Claims (8)

1. A method of treating prostate cancer in a patient comprising: (1) obtaining a sample comprising prostate cancer tumor tissue from said patient; (2) determining by quantitative PCR of cDNA the expression of a panel of genes comprising TPX2 in said sample comprising prostate cancer tumor tissue; (3) prognosing said patient as having a decreased likelihood of prostate cancer progression when the expression of the gene TPX2 is lower than a threshold index value; and (4) administering to said patient active surveillance based on the prognosis.

2. The method of claim 1 , wherein said determining step further comprises determining the expression of one or more housekeeping genes in said sample.

3. The method of claim 2 , wherein said determining step further comprises normalizing the expression of the gene TPX2 using the expression of the housekeeping genes.

4. The method of claim 3 , wherein the housekeeping genes comprise the gene CLTC.

5. A method of treating prostate cancer in a patient comprising: (1) obtaining a sample comprising prostate cancer tumor tissue from said patient; (2) determining by quantitative PCR of cDNA the expression of a panel of genes comprising TPX2 in said sample comprising prostate cancer tumor tissue; (3) prognosing said patient as having an increased likelihood of prostate cancer progression when the expression of the gene TPX2 exceeds a threshold index value; and (4) administering to said patient one or more of chemotherapy, radiation therapy or surgery based on the prognosis.

6. The method of claim 5 , wherein said determining step further comprises determining the expression of one or more housekeeping genes in said sample.

7. The method of claim 6 , wherein said determining step further comprises normalizing the expression of the gene TPX2 using the expression of the housekeeping genes.

8. The method of claim 7 , wherein the housekeeping genes comprise the gene CLTC.

Assignments (5)
SECURITY INTEREST Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (064235/0032) Recorded Aug 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MYRIAD GENETICS, INC.; MYRIAD WOMEN’S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
Reel/Frame 072331/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2023
From: STONE, STEVEN; GUTIN, ALEXANDER; WAGNER, SUSANNE; REID, JULIA
To: MYRIAD GENETICS, INC.
Reel/Frame 064461/0814 →
PATENT SECURITY AGREEMENT Recorded Jul 7, 2023
From: MYRIAD GENETICS, INC.; MYRIAD WOMEN'S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064235/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2022
From: STONE, STEVEN; GUTIN, ALEXANDER; WAGNER, SUSANNE; REID, JULIA
To: INC., MYRIAD GENETICS
Reel/Frame 059600/0428 →